Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
  • A61K9/0007—Effervescent
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
  • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
  • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Definitions

• the present invention relates to pharmaceutical tablet formulations comprising ceftibuten to be used in the treatment of infectious diseases caused by gram positive and gram negative bacteria.
• Ceftibuten was firstly disclosed in the patent application numbered US 4634697. In said document, ceftibuten was indicated to be effective in the treatment of infectious diseases caused by gram positive and gram negative bacteria.
• Ceftibuten is available in the forms of 400 mg capsule, 400 mg tablet and 36 mg/ml oral suspension on the market.
• physical properties of every tablet dosage form are directly related to durability in storage conditions; dissolution and bioavailability of an obtained dosage form.
• the resistance of tablets to storage, transport, coating and erosion-breakage before use is provided by an important physical parameter which is tablet hardness.
• Low hardness of tablets leads to erosion, friability or breakage and causes the loss of active agent and thus decrease in the amount of dose taken.
• In the case of producing coated tablet forms a further consequence of low hardness is the erosion of tablet surface during coating process and this leads to dosage forms that have uneven surfaces and variable amounts of active agent in the final product
• dispersibility and solubility of a tablet is also dependent on the hardness. High hardness of the tablet decreases its dispersion rate hence the time for desired response to occur will eventually extend.
• tablets such as effervescent, film-coated, soluble, extended-release, modified-release, delayed-release tablets etc. Attaining appropriate tablet hardness is influenced by many parameters such as the types of active agents and excipients used, their particle sizes, flowability of the powder or granules prepared for tablet compression and tablet compression force.
• tablet hardness value is aimed to be low enough to disintegrate fast in gastric media or in water in case of effervescent tablet formulations but high enough to preserve tablet integrity from production to use during packaging, carrying and storing phases.
• the inventors have found that the required mechanical tablet resistance, the required dissolution rate and accordingly the desired bioavailability are attained with the tablet formulations comprising ceftibuten in the range of 5-45%, preferably 10-40%, more preferably 10-35% by weight and having a tablet hardness value between 3 kP and 50 kP.
• the tablet formulations of the present invention is characterized in that said tablet formulations comprise ceftibuten as active agent and at least one pharmaceutically acceptable excipient wherein the
• tablet hardness value is in the range of 3 kP and 50 kP.
• tablet formulations of the present invention comprise ceftibuten as active agent and at least one pharmaceutically acceptable excipient and the amount of ceftibuten is in the range of 10-40%, preferably 10-35% by weight.
• a further characteristic of the tablet formulations of the present invention is that said tablet formulations comprise ceftibuten as active agent and at least one pharmaceutically acceptable excipient and have a tablet hardness value in the range of 4 kP and 40 kP, preferably 5 kP and 30 kP.
• tablette used throughout the text refers to tablet types such as tablet, effervescent tablet, film-coated tablet, enteric-coated tablet, orodispersible tablet, water-soluble tablet, extended-release tablet, modified-release tablet, delayed-release tablet.
• the pharmaceutical formulation of the present invention is in effervescent tablet dosage form.
• Ceftibuten comprised in the pharmaceutical formulations of the present invention can be in the form of its pharmaceutically acceptable salts, hydrates, solvates, esters, enantiomers, diastereomers or combinations thereof in terms of chemical structure; and in crystalline, amorphous forms or combinations thereof in terms of polymorphic structure.
• the active agent ceftibuten is preferably in hydrate form, more preferably in the form of ceftibuten dihydrate.
• the pharmaceutical formulations of the present invention comprise at least one pharmaceutically acceptable excipient selected from the group comprising disintegrants, lubricants, binders, effervescent couple composed of at least one effervescent acid and at least one effervescent base, sweeteners and/or taste regulating agents, flavoring agents.
• the lubricant that can be used in the pharmaceutical formulations of the invention can be selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, sodium benzoate, potassium benzoate, sodium lauryl sulphate, talc, stearic acid, zinc stearate or combinations thereof.
• the binder that can be used in the pharmaceutical formulations of the invention can be selected from a group comprising carboxymethyl cellulose sodium, ethyl cellulose, gelatin, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminum silicate, maltodextrin, methyl cellulose, povidone, starch or combinations thereof.
• the effervescent acids that can be used in the pharmaceutical formulations of the invention can be selected from a group comprising organic acids such as malic acid, citric acid, tartaric acid, fumaric acid; and said effervescent bases can selected from a group comprising agents such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate or combinations thereof.
• the sweetener and/or the taste regulating agent that can be used in the pharmaceutical formulations of the invention can be selected from a group comprising acesulfame, aspartame, dextrose, fructose, maltitol, maltose, mannitol, saccharine, saccharine sodium, sodium cyclamate, sorbitol, sucralose, sucrose, xylitol, sodium chloride or combinations thereof.
• the flavoring agent that can be used in the pharmaceutical formulations of the invention can be selected from a group comprising flavors such as menthol, lemon, orange, vanilla, strawberry, raspberry, caramel and the like or combinations thereof.
• the solubility of the tablet is especially dependent on the choice of effervescent couple composed of an effervescent acid and an effervescent base and their amount with regard to the active agent or other excipients.
• the inventors have made studies on the content of the formulation and observed that if the ratio of effervescent couple to ceftibuten is in the range of 10:1 to 1 :1 preferably 8: 1 to 1 : 1 and more preferably 7:1 to 2: 1 by weight; said formulations have the required solubility in water.
• a further embodiment of the present invention is that the ratio of effervescent couple to ceftibuten is in the range of 10:1 to 1 : 1 , preferably 8: 1 to 1 : 1 and more preferably 7: 1 to 2:1 by weight.
• a preferred embodiment of the invention is that the ratio of effervescent base to effervescent acid is in the range of 5:1 to 1 :5, preferably 3:1 to 1 :3 and more preferably 3:1 to 1 : 1 by weight.
• the binder One of the excipients playing role in the homogenity of the formulation and therefore in its solubility is the binder.
• the ratio of ceftibuten to binder should be in the range of 15:1 to 1 :1 by weight for ensuring the integrity of the tablet during manufacturing and before use but also having good disintegration in water for patient compliance.
• the pharmaceutical tablet formulations of the present invention is characterized in that the ratio of ceftibuten to binder is in the range of 15:1 to 1 : 1, preferably 13:1 to 3:1 by weight.
• the tablet formulations of the invention can be produced in accordance with the production method given below;
• the production method used to prepare the ceftibuten formulations is characterized in that the 80 to 50% of the binder, preferably 70 to 60% is used in the granulation step and the rest is used in the mixture to be granulated.
• the pharmaceutical composition of the invention can be used in the prevention and treatment of infectious diseases caused by gram positive and gram negative bacteria.
• the examples below are given to explain the pharmaceutical compositions of the invention and the preparation methods thereof; the scope of the invention cannot be limited to these examples.

Landscapes

• Health & Medical Sciences (AREA)
• Epidemiology (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=48237235

Family Applications (2)

Family Applications Before (1)

Country Status (1)

Cited By (4)

Citations (5)

Family Cites Families (1)

• 2013
  • 2013-01-18 WO PCT/TR2013/000040 patent/WO2013109227A1/fr not_active Ceased
  • 2013-01-18 WO PCT/TR2013/000038 patent/WO2013109225A1/fr not_active Ceased

Patent Citations (5)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events